2026 Q2 - tulosraportti
70 päivää sitten
‧30 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 482 | ||
| 3 658 | ||
| 1 840 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 28.4. | ||
2025 Q4 - tulosraportti 20.2. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 19.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5.10.AcuCort proposes rights issue of SEK 70.3 million today at 08:59 ∙ News Overview (AI) AcuCort has proposed a rights issue of shares and warrants, subject to shareholder approval at an upcoming extraordinary general meeting. The raised capital will finance the regulatory process towards FDA approval and commercialization of the company's oral film drug, Zeqmelit, in the US and other global markets. To cover immediate funding needs until completion, the company has also secured a bridge loan. The rights issue will initially raise approx. SEK 70.3 million, with the possibility of an additional SEK 93.8 million through warrants of series TO 3. The transaction is 75% guaranteed through subscription and guarantee commitments totaling approx. SEK 52.8 million. AcuCort has secured a bridge loan of SEK 5 million to cover short-term financing needs until the rights issue is completed. Shareholders will vote on the rights issue, a reduction of the share capital, and amendments to the articles of association at an extraordinary general meeting on November 5, 2026. Non-participating shareholders face an initial dilution of approx. 50% and a further dilution of 25% if warrants are fully exercised. https://www.acucort.se/sv/acucort-ab-beslutar-om-en-foretradesemission-av-units-om-initialt-cirka-703-msek-for-att-finansiera-fortsatt-arbete-mot-fda-godkannande-och-paskynda-kommersialiseringen-samt-upptar-brygglan/
Then they probably have money for 10 new months, then there will be a new issue in the early summer next year.- ·24.9.Does anyone know how much money they are thinking of raising?
·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |
2026 Q2 - tulosraportti
70 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5.10.AcuCort proposes rights issue of SEK 70.3 million today at 08:59 ∙ News Overview (AI) AcuCort has proposed a rights issue of shares and warrants, subject to shareholder approval at an upcoming extraordinary general meeting. The raised capital will finance the regulatory process towards FDA approval and commercialization of the company's oral film drug, Zeqmelit, in the US and other global markets. To cover immediate funding needs until completion, the company has also secured a bridge loan. The rights issue will initially raise approx. SEK 70.3 million, with the possibility of an additional SEK 93.8 million through warrants of series TO 3. The transaction is 75% guaranteed through subscription and guarantee commitments totaling approx. SEK 52.8 million. AcuCort has secured a bridge loan of SEK 5 million to cover short-term financing needs until the rights issue is completed. Shareholders will vote on the rights issue, a reduction of the share capital, and amendments to the articles of association at an extraordinary general meeting on November 5, 2026. Non-participating shareholders face an initial dilution of approx. 50% and a further dilution of 25% if warrants are fully exercised. https://www.acucort.se/sv/acucort-ab-beslutar-om-en-foretradesemission-av-units-om-initialt-cirka-703-msek-for-att-finansiera-fortsatt-arbete-mot-fda-godkannande-och-paskynda-kommersialiseringen-samt-upptar-brygglan/Then they probably have money for 10 new months, then there will be a new issue in the early summer next year.
- ·24.9.Does anyone know how much money they are thinking of raising?
- ·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
- ·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 482 | ||
| 3 658 | ||
| 1 840 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 28.4. | ||
2025 Q4 - tulosraportti 20.2. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 19.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |
2026 Q2 - tulosraportti
70 päivää sitten
‧30 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 28.4. | ||
2025 Q4 - tulosraportti 20.2. | ||
2025 Q3 - tulosraportti 14.11.2025 | ||
2025 Q2 - tulosraportti 19.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5.10.AcuCort proposes rights issue of SEK 70.3 million today at 08:59 ∙ News Overview (AI) AcuCort has proposed a rights issue of shares and warrants, subject to shareholder approval at an upcoming extraordinary general meeting. The raised capital will finance the regulatory process towards FDA approval and commercialization of the company's oral film drug, Zeqmelit, in the US and other global markets. To cover immediate funding needs until completion, the company has also secured a bridge loan. The rights issue will initially raise approx. SEK 70.3 million, with the possibility of an additional SEK 93.8 million through warrants of series TO 3. The transaction is 75% guaranteed through subscription and guarantee commitments totaling approx. SEK 52.8 million. AcuCort has secured a bridge loan of SEK 5 million to cover short-term financing needs until the rights issue is completed. Shareholders will vote on the rights issue, a reduction of the share capital, and amendments to the articles of association at an extraordinary general meeting on November 5, 2026. Non-participating shareholders face an initial dilution of approx. 50% and a further dilution of 25% if warrants are fully exercised. https://www.acucort.se/sv/acucort-ab-beslutar-om-en-foretradesemission-av-units-om-initialt-cirka-703-msek-for-att-finansiera-fortsatt-arbete-mot-fda-godkannande-och-paskynda-kommersialiseringen-samt-upptar-brygglan/Then they probably have money for 10 new months, then there will be a new issue in the early summer next year.
- ·24.9.Does anyone know how much money they are thinking of raising?
- ·8.9. · Muokattuhttps://analystgroup.se/bolag/acucort/kommentar-pa-acucorts-beviljade-varumarkesskydd-av-zeqmelit-i-ukraina Our view on AcuCort as an investment AcuCort is a pharmaceutical company that has developed the innovative oral film Zeqmelit®, based on the corticosteroid substance dexamethasone for rapid and effective treatment of, among other things, acute allergic reactions. The product has been launched in the Nordics through Unimedic Pharma, where successively rising order values indicate a gradually increasing adoption. The next step is Europe, where the global pharmaceutical company Glenmark Pharmaceuticals is expected to submit the first marketing applications during Q4-26/Q1-27, with an initial focus on Germany. In parallel, a formal NDA application to the FDA is estimated for H2-26, where increasing partner interest is confirmed by over 50 meetings at BIO International and subsequent confidentiality agreements. The cash (10.4 MSEK) is estimated to last until Q4-26, which is why a financing need arises. The situation is, however, stronger than during the last financing, supported by the Glenmark agreement, an upcoming NDA application, and strengthened Nordic foothold. Through a DCF and rNPV valuation, a risk-adjusted net present value of 1.03 kr per share is derived in a Base scenario.
- ·27.8.Someone with Swedbank has bought a decent number last week. One can hope that it's the new addition accumulating.It will be interesting if they will buy in 2029. AcuCort's warrant program fully subscribed yesterday at 13:50 ∙ News overview (AI) AcuCort has successfully completed its latest incentive program with warrants, which achieved full participation from key employees. This milestone reflects strong internal confidence in the company's strategic direction and the commercialization of its flagship product, the oral film Zeqmelit. In addition, the company highlighted its scientific progress with recent journal publications in its latest newsletter. The 2026/2029 warrant program comprises up to 1.8 million warrants, of which 1.5 million have been transferred to four key employees, and 300,000 are reserved for future hires. Each warrant entitles the holder to subscribe for one new share in AcuCort AB between September 1 and December 30, 2029, at a subscription price of 1.34 SEK. The final warrant premium was set at 0.07 SEK per warrant, calculated using the Black-Scholes model by PwC. AcuCort's August 2026 newsletter highlighted two scientific articles recently published in the Journal of Market Access & Health Policy. The company's primary product, Zeqmelit, is an approved and marketed oral film in Sweden, Denmark, Norway, and Finland.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 482 | ||
| 3 658 | ||
| 1 840 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 0 | 5 498 | −5 498 | 0 |
| SSW Market Making GmbH | 0 | 1 482 | −1 482 | 0 |
| Carnegie Investment Bank AB | 1 482 | 0 | 1 482 | 0 |
| Avanza Bank AB | 5 498 | 0 | 5 498 | 0 |